» Authors » Larry N Gever

Larry N Gever

Explore the profile of Larry N Gever including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 7
Citations 61
Followers 0
Related Specialties
Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Finn A, Vasisht N, Stark J, Gever L, Tagarro I
Clin Drug Investig . 2016 Dec; 32(1):63-71. PMID: 27933600
Background And Objectives: Fentanyl buccal soluble film (FBSF) is a small, bilayered, water-soluble polymer film (BioErodible MucoAdhesive; BEMA™) that adheres to the buccal mucosa and rapidly delivers fentanyl into the...
2.
Finn A, Vasisht N, Stark J, Gever L, Tagarro I
Clin Drug Investig . 2011 Dec; 32(1):63-71. PMID: 22128878
Background And Objectives: Fentanyl buccal soluble film (FBSF) is a small, bilayered, water-soluble polymer film (BioErodible MucoAdhesive; BEMA™) that adheres to the buccal mucosa and rapidly delivers fentanyl into the...
3.
Strand A, Bottiger D, Gever L, Wheeler W
Pediatr Dermatol . 2011 Oct; 29(1):105-10. PMID: 22004219
A Phase 3, open-label, multicenter study was conducted to assess the safety of the combination of 5% acyclovir and 1% hydrocortisone cream (AHC cream) in the treatment of recurrent herpes...
4.
Finn A, Hill W, Tagarro I, Gever L
J Pain Res . 2011 Sep; 4:245-51. PMID: 21941456
Purpose: Fentanyl buccal soluble film (FBSF) consists of a small, bilayered, water-soluble polymer film that adheres to the buccal mucosa and rapidly delivers fentanyl into the systemic circulation. The purpose...
5.
Vasisht N, Gever L, Tagarro I, Finn A
Pain Med . 2010 May; 11(7):1017-23. PMID: 20492573
Objective: The objectives of the study were to determine the absolute bioavailability of fentanyl from fentanyl buccal soluble film, estimate the percentage of a fentanyl dose absorbed through the buccal...
6.
Vasisht N, Gever L, Tagarro I, Finn A
J Clin Pharmacol . 2010 Feb; 50(7):785-91. PMID: 20150521
Fentanyl buccal soluble film (FBSF) is a rapidly absorbed transmucosal formulation of fentanyl for the management of breakthrough pain in opioid-tolerant patients with cancer. This open-label, 3-period, sequential dose study...
7.
Vasisht N, Gever L, Tagarro I, Finn A
Clin Drug Investig . 2009 Sep; 29(10):647-54. PMID: 19715381
Background And Objectives: BioErodible MucoAdhesive (BEMA) is a new transmucosal drug delivery system designed to improve and ease the administration of drugs by this route. The first product that uses...